Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (859)	3/17/2000 8:43:00 AM
From: Jim Oravetz	Read Replies (2) \| Respond to of 52153

LIKE MOST DOCTORS, Dr. Faraz Naqvi carries a pager. But rather than alerting him about a patient's status or a shift change at the hospital, Naqvi's pager is more likely to flash stock data relevant to the two mutual funds he runs ? Dresdner RCM Biotechnology (DRBNX) and Dresdner RCM Global Health Care (DGHCX). .... 'European valuations aren't nearly as large as the U.S., and we think the fund flows are eventually going to be aimed there,' observes Naqvi. One new holding is Cell Tech (EFLI), which Naqvi calls the British Amgen. Cell Tech is developing a new class of drugs due out in the next few years that will do things like fight leukemia and colon cancer. Naqvi has also recently added the German Qiagen (QGENF), another company that makes biotech-related research tools. snip... smartmoney.com Jim